[go: up one dir, main page]

WO2003033491A1 - Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition - Google Patents

Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition Download PDF

Info

Publication number
WO2003033491A1
WO2003033491A1 PCT/JP2002/010676 JP0210676W WO03033491A1 WO 2003033491 A1 WO2003033491 A1 WO 2003033491A1 JP 0210676 W JP0210676 W JP 0210676W WO 03033491 A1 WO03033491 A1 WO 03033491A1
Authority
WO
WIPO (PCT)
Prior art keywords
antitumor
medicinal
composition
alleviation
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/010676
Other languages
French (fr)
Japanese (ja)
Inventor
Kazuteru Fukasawa
Yoshikazu Sukenaga
Akira Masuda
Masatoshi Yamada
Kuniko Masuda
Hideji Fujii
Toshiyuki Sakai
Toshio Nikaido
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Kayaku Co Ltd
Original Assignee
Nippon Kayaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2001318445A external-priority patent/JP2003128671A/en
Priority claimed from JP2001327075A external-priority patent/JP2003128581A/en
Application filed by Nippon Kayaku Co Ltd filed Critical Nippon Kayaku Co Ltd
Publication of WO2003033491A1 publication Critical patent/WO2003033491A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Physiologically active substances NK34896A and NK34896B, which each is represented by the general formula (1) (1) or the general formula (2) (2) (wherein X represents hydrogen or an optionally substituted, C1-8, linear or branched, aliphatic hydrocarbon group or optionally substituted, C3-8 alicyclic hydrocarbon group, and Y represents C1-4 alkyl) and analogues of these. They are usable as a preventive or alleviator for side effects of an antitumor and as an antitumor medicine.
PCT/JP2002/010676 2001-10-16 2002-10-15 Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition Ceased WO2003033491A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001318445A JP2003128671A (en) 2001-10-16 2001-10-16 Ester derivatives of bioactive substance nk34896a or nk34896 b, production method therefor and use thereof
JP2001-318445 2001-10-16
JP2001-327075 2001-10-25
JP2001327075A JP2003128581A (en) 2001-10-25 2001-10-25 Prophylactic or alleviating medicine against adverse effect

Publications (1)

Publication Number Publication Date
WO2003033491A1 true WO2003033491A1 (en) 2003-04-24

Family

ID=26623929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/010676 Ceased WO2003033491A1 (en) 2001-10-16 2002-10-15 Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition

Country Status (1)

Country Link
WO (1) WO2003033491A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537965A (en) * 1984-08-03 1985-08-27 Eli Lilly And Company Method of preparing 4aR,8aR-5-permissibly substituted-6-oxo-octahydro-1H(and 2H)-pyrazolo[3,4-g]quinolines, useful as intermediates
JPH02229189A (en) * 1989-03-02 1990-09-11 Microbial Chem Res Found New substance inostamicin, its use and manufacture
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
JP2002069075A (en) * 2000-08-30 2002-03-08 Nippon Kayaku Co Ltd New physiologically active substance nk34896b and method for producing the same
JP2002068980A (en) * 2000-08-30 2002-03-08 Nippon Kayaku Co Ltd Usage of biologically active material, nk34896 analog

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537965A (en) * 1984-08-03 1985-08-27 Eli Lilly And Company Method of preparing 4aR,8aR-5-permissibly substituted-6-oxo-octahydro-1H(and 2H)-pyrazolo[3,4-g]quinolines, useful as intermediates
JPH02229189A (en) * 1989-03-02 1990-09-11 Microbial Chem Res Found New substance inostamicin, its use and manufacture
WO1999015500A1 (en) * 1997-09-05 1999-04-01 Glaxo Group Limited Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
JP2002069075A (en) * 2000-08-30 2002-03-08 Nippon Kayaku Co Ltd New physiologically active substance nk34896b and method for producing the same
JP2002068980A (en) * 2000-08-30 2002-03-08 Nippon Kayaku Co Ltd Usage of biologically active material, nk34896 analog

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EVANS DAVID A. ET AL.: "Synthetic studies in the lysocellin family of polyether antibiotics. The total synthesis of ferensimyc in B", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 113, no. 20, 1991, pages 7613 - 7630, XP002962307 *
SIMIZU SIRO ET AL.: "Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells", JOURNAL OF CANCER RESEARCH, vol. 89, no. 9, 1998, pages 970 - 976, XP002962304 *
WESTLEY JOHN W. ET AL.: "Isolation and characterization of four polyether antibiotics, X-14889A, B, C and D, closely related tolysocellin and the ferensimycins", THE JOURNAL OF ANTIBIOTICS, vol. 46, no. 2, 1993, pages 280 - 286, XP002962306 *
YOSHINORI ITO: "Paclitaxel", JAPANESE JOURNAL OF CLINICAL MEDICINE, vol. 58, 2000, pages 259 - 264, XP002962305 *

Similar Documents

Publication Publication Date Title
PT1257260E (en) PO FORMULATION
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
EP2263667A3 (en) Compositions comprising crystalline trans-(+/-)-delta-9-tetrahydrocannabinol
NZ527157A (en) Compositions for delivering bisphosphonates
DE60211935D1 (en) ALKANDIOL DERIVATIVES FOR THE TREATMENT OF BONE DISEASES
NZ515614A (en) Bisphosphonate compositions with a discontinuous wax coating to aid oesophageal transit
BR9908488A (en) Topiramate pharmaceutical composition
TNSN04213A1 (en) High drug load tablet
YU76503A (en) Pharmaceutically active uridine esters
UA85708C2 (en) Benzoxazine-containing pharmaceutical combinations for treating respiratory tract diseases
EP1666092A3 (en) Drug combination comprising a fatty acid and a uridine compound.
EP0882450A3 (en) Cholesterol-lowering composition comprising coenzyme Q
PL334566A1 (en) Treatment of sclerosis multiplex by oral and inhalatory administration of a copolymer-1
PL370292A1 (en) Formulations for oral administration of active compounds
ZA200105278B (en) Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use.
SG165162A1 (en) Modified release pharmaceutical formulation
CA2336412A1 (en) Medicament for treatment of diabetes
MY128014A (en) Thiol and thiocarbonyl derivatives which are useful as carboxypeptidase u inhibitors
WO2003049676A3 (en) Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the teatment of cancer
EP1839662A4 (en) ANTITUMOR AGENT
EP1291017A3 (en) Use of statins to inhibit formation of osteoclasts
WO2003024457A1 (en) Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
AU8889998A (en) Water soluble analogs and prodrugs of paclitaxel
WO2003033491A1 (en) Medicinal composition for prevention or alleviation of side effect of antitumor and medicinal antitumor composition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA CN KR

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FR GB GR IE IT LU MC NL PT SE SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase